ReviewCurrent cardiology reports2013
Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy.
Review in Current cardiology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Drug-drug interactions between vitamin K antagonists and statins: a systematic review.European journal of clinical pharmacology · 2021Pooled it
- Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.Journal of atherosclerosis and thrombosis · 2018Guideline
- Monitoring strategies in adults eligible for pharmacological lipid-lowering therapy.The Cochrane database of systematic reviews · 2026Review
- Effects of Compound Yeast Culture on the Intestinal Morphology, Intestinal Function, and Microorganisms of Weaned Lambs.Probiotics and antimicrobial proteins · 2026Article
- Patients on statins with elevated transaminases: Frequency of follow-up creatine kinase testing and gastroenterology referral.British journal of clinical pharmacology · 2026Article
- Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.Journal of atherosclerosis and thrombosis · 2024Article
- Abbreviated lipid guidelines for clinical practice : Based on ESC lipid guidelines 2019 and ESC cardiovascular disease prevention in clinical practice guidelines 2021.Irish journal of medical science · 2023Article
- Delphinidin-3-Pharmaceutical biology · 2022Article
- HyperCKemia associated with acupuncture: a case report and review of the literature.BMC complementary medicine and therapies · 2022Review
- Improvement of Platelet Respiration by Cell-Permeable Succinate in Diabetic Patients Treated with Statins.Life (Basel, Switzerland) · 2021Article
- Cell-Permeable Succinate Rescues Mitochondrial Respiration in Cellular Models of Statin Toxicity.International journal of molecular sciences · 2021Article
- Cardiovascular Risk in Fatty Liver Disease: The Liver-Heart Axis-Literature Review.Frontiers in medicine · 2019Review
- Lipid, blood pressure and kidney update 2013.International urology and nephrology · 2014Review
- What are the benefits and drawbacks of statins in carotid artery disease? A perspective review.Expert review of cardiovascular therapyReview
- 2022 Saudi Guidelines for the Management of Dyslipidemia.Heart views : the official journal of the Gulf Heart AssociationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A number of plasma lipid parameters have been used to estimate cardiovascular risk and to be targets for treatment to reduce risk. Most risk algorithms are based on total cholesterol (T-C) or low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C), and most intervention trials have targeted the LDL-C levels. Emerging measures, which in some cases may be better for risk calculation and as alternative treatment targets, are apolipoprotein B and non-HDL-C. Other lipid measures that may contribute in risk analysis are triglycerides (TG), lipoprotein(a), and lipoprotein-associated phospholipase A2. The primary treatment target in cardiovascular prevention is LDL-C, and potential alternative targets are apoB and non-HDL-C. In selected individuals at high cardiovascular (CV) risk, TG should be targeted, but HDL-C, Lp(a), and ratios such as LDL-C/HDL-C or apoB/apoAI are not recommended as treatment targets. Lipids should be monitored during titration to targets. Thereafter, lipids should be checked at least once a year or more frequently to improve treatment adherence if indicated. Monitoring of muscle and liver enzymes should be done before the start of treatment. In stable conditions during treatment, the focus should be on clinical symptoms that may alert muscle or liver complications. Routine measurement of CK or ALT is not necessary during treatment with statins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.